Code sections 4(1)(b), 4(2)(a), 4(2)(c) No sanction undertakings accepted
|
|
- Clemence Booth
- 5 years ago
- Views:
Transcription
1 COMPLAINTS RESOLUTION PANEL DETERMINATION Complaint Blackmores Bilberry Eyestrain Relief ARTG ID: AUST L Meeting held 15 December 2016 Complaint summary^ Complainant Advertiser Subject matter of complaint Type of determination Sections of the Code, Regulations or Act found to have been breached* Sections of the Code, Regulations or Act found not to have been breached* Sanctions Requested anonymity Blackmores Limited Internet advertisements Final Code sections 4(1)(b), 4(2)(a), 4(2)(c) Code section 4(2)(h) No sanction undertakings accepted * only sections of the Code, Act, or Regulations that were part of the complaint or were raised by the Panel are listed Page 1 of 8
2 The advertisement(s)^ 1. The complaint concerned internet advertisements published on the websites and viewed by the complainant on 29 August The Blackmores website advertisement included the representations Blackmores Bilberry Eyestrain Relief is formulated to support visual acuity and Eye strain and fatigue is often caused from fine detailed work, computer work, poor night vision or glare sensitivity. The advertisement also included the heading Why use followed by the dot points: Helps to maintain visual sharpness in poor light (night vision) Supports healthy functioning of the retina May help strengthen the walls of the many small capillaries that help nourish the eye (microcirculation) 3. The Chemist Warehouse and Pharmacy Direct website advertisements included similar representations about the advertised product, such as Daily computer use, night driving and fine detail work can lead to symptoms of eyestrain, Bilberry has traditionally been used to relieve eyestrain, eye fatigue, weariness as well as support night vision, The active compounds in Bilberry work to help strengthen microcirculation and blood vessels in the eye, Helps maintain visual acuity and sharpness in poor light, Supports healthy functioning of the retina and may help reduce the risk of damage to the microcirculation of the eye and The anthocyanosides in bilberry help to maintain visual acuity (sharpness) and improve night vision. 4. An excerpt of the advertisement can be viewed in the relevant Appendix to this determination. The product(s) 5. The advertisement promoted Blackmores Bilberry Eyestrain Relief (AUST L ). The advertiser(s) 6. The advertiser was the sponsor of the product, Blackmores Ltd. The complaint^ 7. The complainant requested anonymity. 8. The complaint alleged that the following representations were in breach of sections 4(1)(b), 4(2)(a), 4(2)(c) and 4(2)(h) of the Code: Bilberry has traditionally been used to relieve eyestrain, eye fatigue and eye weariness Helps maintain visual acuity and sharpness in poor light Supports night vision Page 2 of 8
3 The anthocyanosides in bilberry help to maintain visual acuity and sharpness in poor light (night vision) 9. The complainant provided A summary of the key scientific evidence for &/or against the claims raised in the complaint. The summary was set out in 2 parts. 10. Part 1 of the evidence summary related to the representations that bilberry has traditionally been used to relieve eyestrain, eye fatigue and eye weariness, with the complainant noting that these claims should be substantiated by scientific research. 11. The complainant advised that their search of PubMed and MEDLINE revealed a recent study by Ozawa et al (2015), and provided a copy of the study. The complainant noted that the final comment in the study was further information is required on the application of BE as a common intervention therapy for reducing eye fatigue in VDT workers, this study may contribute to understanding the wider effects of BE. and surmised that This not only highlights that the research is essentially inconclusive and that bilberry extract shouldn t be used as a medical intervention without further research. The complainant also noted that this study was published in November 2015 and that the advertised product was listed in the Register prior to this (mistakenly noting 2005 instead of the correct year, 2008). 12. The complainant also argued that The ambiguity in results was also confirmed by a 2007 review carried out by Gosh and Konishi, whereby the older and less rigorous studies presented with positive correlations between bilberry extract/anthocyanosides and improved eye function, whereas, recent and more credible studies showed little to no causative relationship. Similarly a 2004 review conducted by Canther and Ernst supported the latter need for further research in this medical field. 13. Part 2 of the evidence summary related to the representations that the product helps maintain visual acuity and sharpness in poor light, supports night vision and that the anthocyanosides in bilberry help to maintain visual acuity and sharpness in poor light, with the complainant noting that these claims should be verified by readily published evidence. 14. The complainant advised that their search of PubMed revealed a study by Zadok et al (1999), and provided a copy of the study. The complainant noted that the authors concluded that Multiple oral administrations of 12 and 24mg anthocyanosides twice a day appear to lack significant effects on night vision tests. and argued that It is important to note that there was no studies found on the positive correlation between anthocynanoside dosage and night vision improvement. Therefore the claims made by the sponsor are questionable and potentially unjustified. 15. In relation to Zadok et al (1999), the complainant noted that: The number of patients used in the study was small There were no significant differences between the anthocyanoside treated groups and the control group during the 4 day drug administration period The author encourages that further testing be conducted using a longer period of drug administration and a larger number of participants. It is important to note that no recent studies have been conducted on the effects of anthocyanosides on night vision. Page 3 of 8
4 The dosages used in Zadok s study were 12/24mg administered twice a day daily. That is a maximal dose of 48mg per day. This is synonymous with the maximal dose of anthocyanosides found within Blackmores Bilberry (48.6mg) should three capsules be taken per day. As it was proven in this study that 48mg is not sufficient enough to see improvements in night vision. Blackmores cannot justify the effects of anthocyanosides on night vision. 16. The complainant also advised that A PubMed search was conducted to see if another group had replicated the results of this study and an earlier study was found examining the effects of anthocyanosides on night vision in Levy and Glovinsky (1998) found that single oral administrations of 12-36mg of anthocyanosides appear to lack significant effects on military relevant night vision. 17. The complainant concluded We believe that the sponsor Blackmores has made claims about the effects of Bilberry/anthocyanosides that are not supported by scientific evidence. and We ask the TGACRP to request Blackmores to retract these unsubstantiated claims for these products; ensure that 3rd parties such as Internet pharmacies also correct their promotion (which was presumably sourced from the sponsor). 18. The complainant also alleged breaches in relation to some of the indications included in the Register for the advertised product. However, as the Panel is unable to consider indications in the Register, its consideration of the complaint was confined only to the representations made in the website advertisements. The advertiser was advised accordingly. The advertiser s response to the complaint^ 19. Blackmores provided its response in 2 parts, in line with how the complainant had set out the complaint and evidence summary. 20. In response to Part 1, the advertiser stated: Although the dates are confused, the complainant rightly points out that the study [Ozawa et al. (2015)] was published in 2015 yet Blackmores Bilberry Eyestrain Relief was listed on the ARTG in June 2008, with the most recent effective date as February At the time of listing the ARTG claims for the product were believed to be supported by traditional and textbook evidence. The complainant themselves points out a 2007 review identified positive correlations between bilberry extract/anthocyanosides and improved eye functions, whereas more recent studies suggest further research is required to fully understand the benefit. The receipt of this complaint has prompted us to review the current body of evidence for both traditional and scientific support of bilberry extract and claims around eyestrain, eye fatigue and eye weariness. Given the inconclusive scientific evidence that has been highlighted we agree that claims in relation to eyestrain are no longer adequately substantiated based on the current levels of evidence guidelines. We are now retracting product claims around eyestrain, eye fatigue and eye weariness and we have initiated the process to change the name of the product, a process which will be completed once the current stock of labels is exhausted. 21. In response to Part 2, the advertiser stated:..bilberry has a long history of use and at the time of listing it was believed there was evidence to support a traditional use relating to night vision and visual acuity in poor light. The notion that bilberry can be used to enhance night vision arose from anecdotal reports of British Royal Air Force (RAF) aviators in World War II eating bilberry jam to improve their night vision. In Page 4 of 8
5 addition to this, numerous studies since the 1960s further suggested a benefit of bilberry on night vision. As the complainant points out, recent scientific evidence to support the use of bilberry has not replicated a positive effect. Due to the difficulty in ascertaining the role of bilberry in improving night vision it is now generally recognised that further trials on the extract are warranted. We therefore also agree that claims in relation to night vision and visual acuity in poor light are unsupported based on the current levels of evidence guidelines. As above, we are voluntarily retracting product claims around night vision and are in the process of changing the name of the product, a process which will be completed once the current stock of labels is exhausted. 22. The advertiser concluded Blackmores confirms it is committed to ensuring the claims made in relation to our products are substantiated. We are now taking appropriate action to withdraw the representations for the product, which will include notifying our retail partners and updating the Blackmores website. The website has already been updated to remove claims around eyestrain and night vision, however the product name temporarily remains while we implement a label change to change the name of the product. 23. As part of its response, Blackmores also provided the Panel with the current ARTG summary for the advertised product and an updated ARTG application submitted with revised indications and new product name. Findings of the Panel 24. As a preliminary matter, the Panel noted that the representations made in the advertisements were substantially the same and that the retailer websites only included claims consistent with the sponsor s website and in line with the indications included in the Register for the advertised product. For this reason, the Panel was satisfied that the sponsor, Blackmores Ltd, was responsible for the advertisements. 25. Section 4(1)(b) of the Code requires that advertisements for therapeutic goods contain correct and balanced statements only and claims which the sponsor has already verified. Section 4(2)(a) of the Code prohibits representations that are likely to arouse unwarranted and unrealistic expectations of product effectiveness. Section 4(2)(c) of the Code prohibits representations that mislead directly or by implication or through emphasis, comparisons, contrasts or omissions. 26. The Panel noted the advertiser s response that older evidence was used for traditional use claims at the time of listing the product in the Register but that there is now more recent scientific evidence that doesn t support the representations raised in the complaint. The Panel noted that Blackmores agreed to remove the claims and change the product name and packaging, and that evidence of this was provided. 27. Based on the material before it, the Panel was satisfied that the following representations had not been verified, were not correct and balanced, were likely to arouse unwarranted expectations and were misleading, in breach of sections 4(1)(b), 4(2)(a) and 4(2)(c) of the Code: Bilberry has traditionally been used to relieve eyestrain, eye fatigue and eye weariness Helps maintain visual acuity and sharpness in poor light Supports night vision Page 5 of 8
6 The anthocyanosides in bilberry help to maintain visual acuity and sharpness in poor light (night vision) 28. The Panel found, therefore, that these aspects of the complaint were justified. 29. Section 4(2)(h) of the Code prohibits advertisements for therapeutic goods that contain any claim, statement or implication that it is effective in all cases of a condition. 30. The Panel did not find any words in the advertisement that implied that the advertised product would be effective in all cases of a condition. 31. The Panel found, therefore, that this aspect of the complaint was not justified. Sanctions 32. Given the undertakings provided by Blackmores Limited, the Panel decided to apply no sanction. Dated 28 April 2017 For the Panel Allan Asher Chairman Page 6 of 8
7 Appendix A: Definitions and footnotes In this determination, unless otherwise specified: a) the Act means the Therapeutic Goods Act 1989; b) the Regulations means the Therapeutic Goods Regulations 1990; c) the Code means the Therapeutic Goods Advertising Code; d) the Register means the Australian Register of Therapeutic Goods; e) any other advertisement appearing in sub-regulation 42ZCA1(1)(d) is not confined to advertisements in specified or broadcast media (in relation to which complaints may be made to the Panel under Regulation 42ZCAB). It should be noted that HTML metatags and other information which can be retrieved by internet search engines, whether or not it is ordinarily viewed directly by consumers, constitutes advertisement material. ^Readers of the determination should note that the sections complaint summary, the advertisement(s), the complaint, and [a party] s response to the complaint, are summaries that are intended to aid readers of this document. In reaching its decision, the Panel considered all of the material before it, including material that may not be mentioned specifically in the summaries. The summaries do not form part of the Panel s reasoning. *Under regulation 42ZCAI of the Regulations, the Panel may request that a representation not be used in any other advertisement unless the advertiser satisfies the Panel that the use of the representation would not result in a contravention of the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990 or the Therapeutic Goods Advertising Code. Under the Panel s procedures, the Panel will not ordinarily give additional consideration to such a matter unless significant new material that was not available at the time of the Panel s determination has become available, or until at least 12 months have passed since the Panel s request was made. Page 7 of 8
8 Appendix B: Excerpt of the Advertisement Page 8 of 8
Pharmacare Laboratories Pty Ltd. Code sections 4(1)(b), 4(2)(a), 4(2)(c), 4(2)(d), 4(4), 5(2) Withdrawal of advertisements
COMPLAINTS RESOLUTION PANEL DETERMINATION Complaint 2016-10-023 Horny Goat Weed for Him ARTG ID: AUST L 134979 Meeting held 19 January 2017 Complaint summary^ Complainant Advertisers Requested anonymity
More informationCode sections 4(1)(b), 4(2)(a), 4(2)(c), 4(2)(e)(ii) Withdrawal of advertisement. Withdrawal of representations
COMPLAINTS RESOLUTION PANEL DETERMINATION Complaint 2016-09-025 Fertility Formula Male ARTG ID: AUST L 205447 Meeting held 17 November 2016 Complaint summary^ Complainant Advertiser Subject matter of complaint
More informationPharmacare Laboratories Pty Ltd (Cat Media Pty Ltd) Australian Pharmaceutical Industries Ltd (Priceline) Code sections 4(2)(g), 4(2)(h)
COMPLAINTS RESOLUTION PANEL DETERMINATION Complaint 2016-10-019 Horny Goat Weed for Her ARTG ID: AUST L 134980 Meeting held 19 January 2017 Complaint summary^ Complainant Advertisers Requested anonymity
More informationDr Ken Harvey Requested anonymity. Code sections 4(1)(b), 4(2)(a), 4(2)(c), 4(2)(f)
COMPLAINTS RESOLUTION PANEL DETERMINATION Complaints 2012-08-010 Nurofen 2012-10-024 Nurofen Meeting held 17 January 2013 Complaint summary^ Complainants 2012-08-010 - Dr Ken Harvey 2012-10-024 - Requested
More informationASMI COMPLAINTS PANEL FINAL DETERMINATION Meeting held December 13, 2011
ASMI COMPLAINTS PANEL FINAL DETERMINATION Meeting held December 13, 2011 Schering Plough Pty Ltd ( MSD ) v. Johnson & Johnson Pacific Pty Limited ( JJP ) Zyrtec advertising. 1. MSD complains that an advertisement
More informationASMI COMPLAINTS PANEL FINAL DETERMINATION Meeting held May 11, 2010
ASMI COMPLAINTS PANEL FINAL DETERMINATION Meeting held May 11, 2010 Wyeth Consumer Healthcare Pty Limited ( Wyeth ) v. Bayer Australia Limited ( Bayer ) Citracal promotional claims. 1. Wyeth complains
More informationCHE8000 Major Research Project A. The Complementary Medicines Reforms and Its Impact to the Complementary Medicine Industry and the Consumer
CHE8000 Major Research Project A The Complementary Medicines Reforms and Its Impact to the Complementary Medicine Industry and the Consumer Completed by: Lina Karlina (ID: 2067226) Lina Karlina (2067226)
More informationHOUSE AND PROPERTY INSPECTION CASE SUMMARIES 2017
HOUSE AND PROPERTY INSPECTION CASE SUMMARIES 2017 Note: Reference to one gender implies both genders, unless indicated otherwise. CASE #15-26 (2) That the Respondent, a Certified House Inspector (CHI),
More informationASMI Complaints Panel Final Determination. Meeting held on July 14, 2015
ASMI Complaints Panel Final Determination Meeting held on July 14, 2015 AFT Pharmaceuticals Pty Limited ( AFT ) v. Reckitt Benckiser (Australia) Pty Limited ( RB ) Nuromol advertising Jurisdictional issue
More informationSHIRE v FERRING. Promotion of Pentasa CASE AUTH/2299/2/10
CASE AUTH/2299/2/10 SHIRE v FERRING Promotion of Pentasa Shire complained about the promotion of Pentasa (mesalazine) by Ferring. The items at issue were a 'power of five' booklet, an A4 sheet and an advertisement
More informationAnimal Products Notice
Animal Products Notice Labelling Requirements for Exports of Dairy Based Infant Formula Products and Formulated Supplementary Food for Young Children 18 December 2014 An animal products notice issued under
More informationComplainant v. the College of Dental Surgeons of British Columbia
Health Professions Review Board Suite 900, 747 Fort Street, Victoria, BC V8W 3E9 Complainant v. the College of Dental Surgeons of British Columbia DECISION NO. 2015-HPA-221(a) September 13, 2016 In the
More informationTherapeutic Goods Act Therapeutic Goods Advertising Code 2015
Therapeutic Goods Act 1989 Therapeutic Goods Advertising Code 2015 1. I, Lawrence Kelly, delegate of the Minister for Health for the purposes of section 42BAA of the Therapeutic Goods Act 1989 and acting
More informationCOMPLAINT NUMBER 17/008 COMPLAINANT. J Fuller ADVERTISER. Dr Ronald Goedeke, hcg Team ADVERTISEMENT. Diethcg.co.nz Website
COMPLAINT NUMBER COMPLAINANT ADVERTISER ADVERTISEMENT J Fuller Dr Ronald Goedeke, hcg Team Diethcg.co.nz Website DATE OF MEETING 14 March 2017 OUTCOME Upheld SUMMARY The website advertisement for The hcg
More informationINTERNSHIP DUE PROCESS GUIDELINES
INTERNSHIP DUE PROCESS GUIDELINES DEFINITION OF PROBLEM For purposes of this document Intern problem is defined broadly as an interference in professional functioning which is reflected in one or more
More informationBRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI
CASE AUTH/2638/9/13 and AUTH/2639/9/13 BRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI Promotion of Lyxumia Bristol-Myers Squibb and AstraZeneca jointly complained about cost comparison claims in a Lyxumia
More informationGENERAL PRACTICTIONER AND GP PRESCRIBING LEAD v TAKEDA
CASE AUTH/2367/10/10 GENERAL PRACTICTIONER AND GP PRESCRIBING LEAD v TAKEDA Use of inverted black triangle A general practitioner and GP prescribing lead, complained about a two page advertisement for
More informationComplaint to TGA: Weleda Arnica Homeopathic Products
Complaint to TGA: Weleda Arnica Homeopathic Products This is a high priority complaint to test the TGA's will to act on recalcitrant sponsors of complementary medicines. The CRP has upheld more than 15
More informationFood labelling Substantiating your health claim
Food labelling Substantiating your health claim Genevieve James-Martin Research Dietitian I Nutrition & Health Program 4 June 2018 HEALTH & BIOSECURITY Food Labelling Advisory Group Developing new foods
More informationWhat if someone complains about me? A guide to the complaint process
What if someone complains about me? A guide to the complaint process Introduction The purpose of the licensed building practitioner scheme is to set performance standards for building practitioners and
More informationSHIRE v PROCTER & GAMBLE
CASE AUTH/2267/9/09 SHIRE v PROCTER & GAMBLE Promotion of Asacol Shire complained about two leavepieces and a journal advertisement promoting Asacol (modified release mesalazine) issued by Procter & Gamble.
More informationWorkplace Health, Safety & Compensation Review Division
Workplace Health, Safety & Compensation Review Division WHSCRD Case No: WHSCC Claim No: Decision Number: 15240 Bruce Peckford Review Commissioner The Review Proceedings 1. The worker applied for a review
More informationAccredited Registers Programme
Accredited Registers Programme Accreditation Panel s Decision Application for renewal from: Society of Homeopaths ( the Society ) Panel meeting: 30 January 2018 (accreditation renewed with one Condition)
More informationComplaint to TGA: Pharmacare Laboratories Promensil Menopause products
Complaint to TGA: Pharmacare Laboratories Promensil Menopause products This is a high priority complaint to test the TGA's will to act on recalcitrant sponsors of complementary medicines. These products
More informationGDC Disclosure and Publication Policy
GDC Disclosure and Publication Policy 1 DISCLOSURE AND PUBLICATION POLICY TABLE OF CONTENTS PURPOSE... 4 THE LAW... 4 PUBLICATION OF FITNESS TO PRACTISE INFORMATION... 5 Publication of Conduct and Performance
More informationInformation about cases being considered by the Case Examiners
Information about cases being considered by the Case Examiners 13 October 2016 1 Contents Purpose... 3 What should I do next?... 3 Background... 4 Criteria that Case Examiners will consider... 5 Closing
More informationRecall Guidelines. for Chinese Medicine Products
Recall Guidelines for Chinese Medicine Products April 2018 Recall Guidelines for Chinese Medicine Products Chinese Medicines Board Chinese Medicine Council of Hong Kong Compiled in September 2005 1 st
More informationClaims about health in ads for e-cigarettes. CAP and BCAP s regulatory statement
Claims about health in ads for e-cigarettes CAP and BCAP s regulatory statement Contents 1. Executive Summary... 2 2. Policy background and the decision to consult... 4 3. Decisions... 6 4. Consequence
More informationGuideline for the Sale and Supply of Practitioner Only Products
Guideline for the Sale and Supply of Practitioner Only Products Edition 1, December 2011 This document provides guidance to the complementary medicine industry on the sale and supply of practitioner only
More informationASTRAZENECA v CHIESI. Promotion of Fostair CASE AUTH/2618/7/13
CASE AUTH/2618/7/13 ASTRAZENECA v CHIESI Promotion of Fostair AstraZeneca complained about a Fostair (formoterol/beclometasone pressurised inhalation solution) leavepiece issued by Chiesi. AstraZeneca
More information5.I.1. GENERAL PRACTITIONER ANNOUNCEMENT OF CREDENTIALS IN NON-SPECIALTY INTEREST AREAS
Report of the Council on Ethics, Bylaws and Judicial Affairs on Advisory Opinion 5.I.1. GENERAL PRACTITIONER ANNOUNCEMENT OF CREDENTIALS IN NON-SPECIALTY INTEREST AREAS Ethical Advertising under ADA Code:
More informationCase Report ISSUES RAISED. Food and Beverage Code 2.1 (a) - Misleading / deceptive DESCRIPTION OF THE ADVERTISEMENT
Case Report 1 Case Number 0128/15 2 Advertiser Nestle Australia Ltd 3 Product Food and Beverages 4 Type of Advertisement / media TV - Free to air 5 Date of Determination 15/04/2015 6 DETERMINATION Dismissed
More informationSection 32: BIMM Institute Student Disciplinary Procedure
Section 32: BIMM Institute Student Disciplinary Procedure Introduction Academic Development & Quality Assurance Manual This Student Disciplinary Procedure provides a framework for the regulation of BIMM
More information1. We refer to your request made under the Official Information Act 1982 of 29 August 2018 for the following information:
26 September 2018 Official Information Act #18.046 Homeopathic Products 1. We refer to your request made under the Official of 29 August 2018 for the following information: 1.1. The number of complaints
More informationThe Complainant said the claims were misleading as The overall scientific literature doesn t show that Arnica helps the body.
COMPLAINT NUMBER COMPLAINANT ADVERTISER ADVERTISEMENT D. Ryan Pharmacy Direct Pharmacy Direct Website DATE OF MEETING 11 October 2016 OUTCOME Not Upheld in part / Settled in part SUMMARY The website advertisements
More informationComplaint to TGA: Brauer (Homeopathic) Products
Complaint to TGA: Brauer (Homeopathic) Products This is a high priority complaint to test the TGA's will to act on recalcitrant sponsors of complementary medicines. The CRP has upheld more than 15 complaints
More informationEVMS Authorship Guidelines
EVMS Authorship Guidelines Many medical schools, including Eastern Virginia Medical School, encourage the publication and dissemination of results from research and other scholarly activities in a manner
More informationCONSULTANT PHYSICIAN v SANOFI
CASE AUTH/2477/2/12 CONSULTANT PHYSICIAN v SANOFI Conduct of representative A consultant physician alleged that at a hospital diabetes meeting a Sanofi representative had been unprofessional in that she
More informationNOVARTIS v BRISTOL-MYERS SQUIBB
CASE AUTH/2016/7/07 NOVARTIS v BRISTOL-MYERS SQUIBB Sprycel leavepiece Novartis complained about a Sprycel (dasatinib) leavepiece issued by Bristol-Myers Squibb. Sprycel was indicated for use in patients
More informationAPPENDIX B TAP 31 RESOLUTION PROCESS
I. General Principles APPENDIX B TAP 31 RESOLUTION PROCESS a. Administration: The TAP 31 Resolution Process is administered by the University s Title IX Coordinator and the University s Deputy Title IX
More informationThe Complainant said there was no evidence to support the therapeutic claims made by Bioptron.
COMPLAINT NUMBER 15/463 COMPLAINANT ADVERTISER ADVERTISEMENT D. Ryan Balanced Energy Balanced Energy Website DATE OF MEETING 26 January 2016 OUTCOME Upheld SUMMARY The website advertisement by Balanced
More informationBritish American Tobacco Snus Marketing Standards
British American Tobacco Snus Marketing Standards British American Tobacco p.l.c. believes there is sufficient scientific evidence to support a less restrictive regime for the advertising and promotion
More informationOverview. You can find the regulations and more details on the LJMU website, here
DISCIPLINARIES Overview Whilst at LJMU, students are expected to abide by the student code of behaviour. This is a set of standards regarding personal and professional behaviour. If you are perceived to
More informationAppeal and Grievance Procedure
Appeal and Grievance Procedure DEFINITIONS. Complainant is defined as any resident or prospective resident in the project whose rights duties, welfare, or status are or may be adversely affected by management
More informationUK Council for Psychotherapy Ethical Principles and Code of Professional Conduct
UK Council for Psychotherapy Ethical Principles and Code of Professional Conduct Some material in this document derives from the UK Health Professions Council document Standards of conduct, performance,
More informationNew regulatory requirements DPCS Regulations 2017
New regulatory requirements DPCS Regulations 2017 Prescribers and pharmacists May 2017 Table of Contents Explanatory notes... 1 Clarifying the meaning of key terms... 1 Chart instructions and prescriptions...
More informationNIIM HREC: TGA AUTHORISED PRESCRIBER SCHEME APPLICATION APPROVAL PROCEDURES 1. Procedures Statement
NIIM HREC: TGA AUTHORISED PRESCRIBER SCHEME APPLICATION APPROVAL PROCEDURES 1. Procedures Statement The aim of these procedures is to set out the processes for applications to the NIIM Human Research Ethics
More informationParent/Student Rights in Identification, Evaluation, and Placement
Parent/Student Rights in Identification, Evaluation, and Placement The following is a description of the rights granted to students with a disability by Section 504 of the Rehabilitation Act of 1973, a
More informationConsultation: Discontinuing pre-market evaluation of Herbal Component Names (HCNs)
Complementary Medicines Australia submission to the Therapeutic Goods Administration Consultation: Consultation: Discontinuing pre-market evaluation of Herbal Component Names (HCNs) 12 January 2018 To:
More informationPreparing for an Oral Hearing: Taxi, Limousine or other PDV Applications
Reference Sheet 12 Preparing for an Oral Hearing: Taxi, Limousine or other PDV Applications This Reference Sheet will help you prepare for an oral hearing before the Passenger Transportation Board. You
More informationTower Hamlets Prostitution Partnership Operating Protocol
Tower Hamlets Prostitution Partnership Operating Protocol 1 Contents Introduction 3 Aims 3 Membership of the THPP 3 Members Responsibility 4 Attendance by other professionals 4 Attendance by those referred
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: No Coverage Criteria/Off-Label Use Policy Reference Number: CP.PMN.53 Effective Date: 07.01.18 Last Review Date: 05.01.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationANONYMOUS v PROSTRAKAN
CASE AUTH/2510/6/12 ANONYMOUS v PROSTRAKAN Promotion of Abstral NO BREACH OF THE CODE An anonymous physician alleged that an un-named ProStrakan representative had misled him/her with regard to the titration
More informationHEALTH PROFESSIONAL V ASTRAZENECA
CASE AUTH/3034/4/18 HEALTH PROFESSIONAL V ASTRAZENECA Patient engagement webpages An anonymous complaint was received about a page on AstraZeneca UK Limited s Medicines website. Within the diabetes section
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationCODE OF PRACTICE REVIEW
NUMBER 87 February 2015 CODE OF PRACTICE REVIEW The Prescription Medicines Code of Practice Authority was established by The Association of the British Pharmaceutical Industry (ABPI) in 1993 to operate
More informationGrievance Procedure of the Memphis Housing Authority
Grievance Procedure of the Memphis Housing Authority 1. Definitions applicable to the grievance procedure: [966.53] A. Grievance: Any dispute which a Tenant may have with respect to MHA action or failure
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Policy Reference Number: CP.PMN.53 Effective Date: 09.12.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this
More informationGood Practice Notes on School Admission Appeals
Good Practice Notes on School Admission Appeals These notes are for supplementary information only and have no statutory basis. Full guidance is available from the Department for Education www.dfe.gov.uk
More informationBAYER v BOEHRINGER INGELHEIM
CASE AUTH/2231/5/09 BAYER v BOEHRINGER INGELHEIM Promotion of Pradaxa Bayer complained about the promotion of Pradaxa (dabigatran) by Boehringer Ingelheim. The items at issue were a medical information
More informationPROSTRAKAN v SHIRE. Calcichew-D 3 Forte journal advertisement CASE AUTH/1825/4/06
CASE AUTH/1825/4/06 PROSTRAKAN v SHIRE Calcichew-D 3 Forte journal advertisement ProStrakan complained about a journal advertisement for Calcichew-D 3 Forte (calcium carbonate, colecalciferol) issued by
More informationThe Chartered Society of Physiotherapy Complaints Procedure
14 Bedford Row, London WC1R 4ED Tel +44 (0)20 7306 6666 Web www.csp.org.uk The Chartered Society of Physiotherapy Complaints Procedure issuing function Chief Executives Office date of issue May 2009 The
More informationThis paper contains analysis of the results of these processes and sets out the programme of future development.
Fitness to Practise Committee, 14 February 2013 HCPC witness support programme Executive summary and recommendations Introduction This paper outlines the approach taken by HCPC in relation to witness management
More informationInquiry Policy OSCR. Scottish Charity Regulator
Inquiry Policy OSCR Scottish Charity Regulator Inquiry Policy Charities are independent organisations run by charity trustees. They play an important role in our society, and many of us are involved with
More informationAppendix C Resolution of a Complaint against an Employee
Appendix C Resolution of a Complaint against an Employee Appendix C: Resolution of a Complaint Against an Employee As outlined in the Union College Sexual Misconduct Policy, an individual who wishes to
More informationTherapeutic Goods Act Therapeutic Goods Advertising Code 2007
Therapeutic Goods Act 1989 Therapeutic Goods Advertising Code 2007 I, Christopher Pyne, Assistant Minister for Health and Ageing for the purposes of the exercise of the Minister s powers under subsection
More informationNon-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients
Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients Pharmaceutical Society of Ireland Version 3 October 2017 Updates made following the enactment
More information4. Together, defendants CCA and CCC represent the vast majority of chiropractors practicing in Connecticut.
RETURN DATE JULY 6, 2010 VICTIMS OF CHIROPRACTIC ABUSE, LLC, J.D. OF HARTFORD Plaintiff, at HARTFORD v. CONNECTICUT CHIROPRACTIC ASSOCIATION, INC.; CONNECTICUT CHIROPRACTIC COUNCIL, INC., Defendants JUNE
More informationSeal of Approval Guidelines. The Approval Program
Seal of Approval Guidelines The Approval Program 1. Program Objectives 1.1 To recognise over the counter products with an Oral Health Benefit where products can be established to be safe, efficient and
More informationFitness to Practise Committee Rules and Practice Direction Revised September 2012
Fitness to Practise Committee Rules and Practice Direction Revised September 2012 Table of Contents RULE 1 DEFINITIONS 1 RULE 2 ELECTRONIC HEARINGS 2 RULE 3 DUTY OF EXPERT 4 PRACTICE DIRECTION 5 No. 1
More informationTenant & Service User Involvement Strategy
Tenant & Service User Involvement Strategy Policy No: HM 07 Page: 1 of 9 Tenant & Service User Involvement Strategy 1. Introduction 1.1 Loreburn's Mission Statement is "Delivering Excellence" and we see
More informationDISCIPLINE COMMITTEE OF THE COLLEGE OF TRADITIONAL CHINESE MEDICINE PRACTITIONERS AND ACUPUNCTURISTS OF ONTARIO
DISCIPLINE COMMITTEE OF THE COLLEGE OF TRADITIONAL CHINESE MEDICINE PRACTITIONERS AND ACUPUNCTURISTS OF ONTARIO PANEL: Henry Maeots Chairperson, Public Member Xianmin Yu Barrie Haywood Professional Member
More informationAdverse Event Reporting Programme for Veterinary Medicines
Adverse Event Reporting Programme for Veterinary Medicines ACVM guideline for registrants 1. Introduction 2. Statutory basis for adverse event reporting 3. Definitions 4. Statutory obligations 5. Information
More informationMEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA
MEDICINES CONTROL AGENCY GUIDELINE FOR REGISTRATION OF FOOD/NUTRITIONAL/DIETARY SUPPLEMENTS IN THE GAMBIA Document No.: MCA/NSG/17/11/01 Date of Adoption: 20 th January 2017 Date of Issue: 25 th July 2017
More informationRESOLUTION AGREEMENT
RESOLUTION AGREEMENT Paul Public Charter School OCR Case No. 11 12 1444 Paul PCS (the School) agrees to fully implement this (Agreement) to resolve OCR Complaint No. 11 12 1444. GENERAL PROVISIONS 1. This
More informationDE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES
DE-DESIGNATION OF YELLOW FEVER VACCINATION CENTRES January 2014 INDEX Page 1. Introduction 3 2. De-designating a YFVC 4 3. The de-designation process 5-6 4. Repeated breaches of the standards for designation
More informationMEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH
11 MEDICINES, MEDICAL DEVICES, TREATMENTS AND HEALTH Background The rules in this section are designed to ensure that advertisements that include health claims (please see Section 13 for health claims
More informationAPPENDIX A. THE UNIVERSITY OF OKLAHOMA Student Rights and Responsibilities Code PROCEDURES
APPENDIX A THE UNIVERSITY OF OKLAHOMA Student Rights and Responsibilities Code PROCEDURES 2017-2018 STUDENT RIGHTS AND RESPONSIBILITIES CODE PROCEDURES - 1 I. Procedural Flexibility The Chair of the Hearing
More informationCODE OF PRACTICE REVIEW
NUMBER 86 November 2014 CODE OF PRACTICE REVIEW The Prescription Medicines Code of Practice Authority was established by The Association of the British Pharmaceutical Industry (ABPI) in 1993 to operate
More informationMS Society Safeguarding Adults Policy and Procedure (Scotland)
MS Society Safeguarding Adults Policy and Procedure (Scotland) Safeguarding Adults Policy The phrase adult support and protection is used instead of safeguarding in Scotland. However for consistency across
More informationGraduate Student Academic Grievance Hearing Procedures. For the College of Education
Graduate Student Academic Grievance Hearing Procedures For the College of Education The Michigan State University Student Rights and Responsibilities (SRR) and the Graduate Student Rights and Responsibilities
More informationA guide to GDC investigations and fitness to practise proceedings
A guide to GDC investigations and fitness to practise proceedings Contents Introduction 2 What is the GDC s role? 3 Stage 1 Raising Concerns 5 Stage 2 Investigation 6 Stage 3 Conclusion of Investigation
More informationGUIDELINES FOR USE OF NUTRITION AND HEALTH CLAIMS
1 CAC/GL 23-1997 GUIDELINES FOR USE OF NUTRITION AND HEALTH CLAIMS CAC/GL 23-1997 Nutrition claims should be consistent with national nutrition policy and support that policy. Only nutrition claims that
More informationGRANGE PARK SURGERY LOCAL PATIENT PARTICIPATION REPORT
GRANGE PARK SURGERY LOCAL PATIENT PARTICIPATION REPORT Date: February 2012 1. Introduction The Patient Participation Group (PPG) at Grange Park Surgery was established in 2009 with the first open meeting
More informationDIRECTOR v NOVO NORDISK
CASE AUTH/2269/9/09 DIRECTOR v NOVO NORDISK Breach of undertaking The Constitution and Procedure was such that when the Director received information from which it appeared that a company might have contravened
More informationDrug and Alcohol Policy
Drug and Alcohol Policy Purpose Skillset Pty Ltd ( Skillset ) is committed to providing a safe and healthy work environment, so far as is reasonably practicable in which all workers are treated fairly,
More informationThe Australian Market & Social Research Society (AMSRS) Introduction AMSRS Guidelines and regulations General...
Contents The Australian Market & Social Research Society (AMSRS)... 3 Introduction... 4 AMSRS Guidelines and regulations... 4 General... 4 Purpose of the Code... 5 Scope of the Code... 5 Interpretation...
More informationSEXUAL HARASSMENT POLICY
SEXUAL HARASSMENT POLICY Policy No.: 750 Date: 10-19-11 Supersedes: Date: APPLICABLE TO FOLLOWING GROUPS: All Employees POLICY Sexual harassment is unlawful and such prohibited conduct exposes both the
More information1. Procedure for Academic Misconduct Committees, virtual panels and formal hearings
1. Procedure for Academic Misconduct Committees, virtual panels and formal hearings This procedure should be read in conjunction with the Academic Misconduct Procedure. Staff and students should ensure
More informationANNUAL REPORT FOR 2011
NUMBER 77 August 2012 CODE OF PRACTICE REVIEW The Prescription Medicines Code of Practice Authority was established by The Association of the British Pharmaceutical Industry (ABPI) in 1993 to operate the
More informationInternational Paralympic Committee Athletics Classification Rules and Regulations. January 2016
I P C AT H L E T I C S International Paralympic Committee Athletics Classification Rules and Regulations January 2016 Official IPC Athletics Partner www.paralympic.org/athletics www.ipc-athletics.org @IPCAthletics
More informationIN THE MATTER OF THE HEALTH PROFESSIONS ACT, R.S.A. 2000, c.h-7;
IN THE MATTER OF THE HEALTH PROFESSIONS ACT, R.S.A. 2000, c.h-7; AND IN THE MATTER OF A HEARING INTO THE CONDUCT OF ACSW Member, A MEMBER OF THE ALBERTA COLLEGE OF SOCIAL WORKERS; AND INTO THE MATTER OF
More informationDISCIPLINE COMMITTEE OF THE COLLEGE OF OPTOMETRISTS OF ONTARIO THE COLLEGE OF OPTOMETRISTS OF ONTARIO -AND-
DISCIPLINE COMMITTEE OF THE COLLEGE OF OPTOMETRISTS OF ONTARIO B E T W E E N: THE COLLEGE OF OPTOMETRISTS OF ONTARIO -AND- DR. EMAD ESKANDER, DR. KAR MAN CHEUNG, DR. SUZAN SARKIES, DR. VIVIAN LI NOTICE
More informationIN THE MATTER OF THE INTERNATIONAL MIXED MARTIAL ARTS FEDERATION ANTI DOPING PROCEEDINGS CONCERNING BREACH OF ARTICLE 2.1 BETWEEN:
IN THE MATTER OF THE INTERNATIONAL MIXED MARTIAL ARTS FEDERATION ANTI DOPING PROCEEDINGS CONCERNING BREACH OF ARTICLE 2.1 BETWEEN: THE INTERNATIONAL MIXED MARTIAL ARTS FEDERATION --AND-- JAMIE HERRINGTON
More informationAmerican Emu Association. Certified Emu Oil Program
Table of Contents Part 1. Frequently Asked Questions... 3 Part 2. AEA Certified Fully Refined Seal & Verbiage Usage Requirements... 5 Section A. Program Requirements... 5 Section B. Product Labeling Requirements...
More informationLEAF Marque Chain of Custody Self Assessment v1.0 Downloadable Copy B
LEAF Marque Chain of Custody Self Assessment v1.0 Downloadable Copy B This downloadable copy of the LEAF Marque Chain of Custody Self Assessment v1.0 is applicable to businesses that do not grow crops
More informationFIH CODE OF CONDUCT, FIH ANTI-DOPING RULES, FIH IMAGE RIGHTS POLICY AND FIH ANTI-CORRUPTION REGULATIONS
Notes: FIH CODE OF CONDUCT, FIH ANTI-DOPING RULES, FIH IMAGE RIGHTS POLICY AND FIH ANTI-CORRUPTION REGULATIONS ACKNOWLEDGMENT AND AGREEMENT 1. No Participant may participate in an FIH world level event
More informationIAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005
IAASB Main Agenda (March 2005) Page 2005 579 Agenda Item 13-F DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005 Introduction This memorandum provides some background to, and
More informationINTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION CONTENTS
INTERNATIONAL STANDARD ON ASSURANCE ENGAGEMENTS 3000 ASSURANCE ENGAGEMENTS OTHER THAN AUDITS OR REVIEWS OF HISTORICAL FINANCIAL INFORMATION (Effective for assurance reports dated on or after January 1,
More information